Carrera Capital Advisors Takes Position in Takeda Pharmaceutical Co. $TAK

Carrera Capital Advisors acquired a new stake in Takeda Pharmaceutical Co. (NYSE:TAK) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 139,145 shares of the company’s stock, valued at approximately $2,153,000.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its holdings in Takeda Pharmaceutical by 3.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 22,088 shares of the company’s stock worth $341,000 after buying an additional 715 shares in the last quarter. Sage Rhino Capital LLC boosted its holdings in Takeda Pharmaceutical by 7.9% during the second quarter. Sage Rhino Capital LLC now owns 12,604 shares of the company’s stock worth $195,000 after buying an additional 919 shares in the last quarter. Jackson Thornton Wealth Management LLC boosted its holdings in Takeda Pharmaceutical by 7.8% during the second quarter. Jackson Thornton Wealth Management LLC now owns 12,779 shares of the company’s stock worth $192,000 after buying an additional 920 shares in the last quarter. Intelligence Driven Advisers LLC boosted its holdings in Takeda Pharmaceutical by 7.2% during the second quarter. Intelligence Driven Advisers LLC now owns 14,535 shares of the company’s stock worth $225,000 after buying an additional 977 shares in the last quarter. Finally, Ieq Capital LLC boosted its holdings in Takeda Pharmaceutical by 4.6% during the first quarter. Ieq Capital LLC now owns 22,222 shares of the company’s stock worth $330,000 after buying an additional 981 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TAK has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Takeda Pharmaceutical in a report on Tuesday, October 14th. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $14.03 on Friday. The firm has a 50-day simple moving average of $14.75 and a 200-day simple moving average of $14.73. The stock has a market capitalization of $44.63 billion, a price-to-earnings ratio of 46.75 and a beta of 0.21. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.